# Feds Release Final Meaningful Use Standards

BY MARY ELLEN SCHNEIDER

the federal government has released the much-anticipated requirements for how physicians and hospitals can qualify for tens of thousands of dollars in incentive payments to adopt and use electronic health records.

The final rule on the meaningful use of electronic health records (EHRs) eases many of the requirements that officials in the Health and Human Services department had outlined in a proposal published in January. Physician organizations had objected to the initial proposal, saying that it asked doctors to do too much too quickly.

Physicians were also critical of the all or nothing framework of the proposal, which required them to meet all 25 objectives for meaningful use or lose out on incentive payments.

Federal officials aimed to address those

concerns in the final rule by requiring physicians to first meet a core set of 15 requirements and then meet any 5 of 10 additional requirements. The core set includes requirements such as recording patient demographics and vital signs in the EHR and maintaining an up-to-date problem list and an active list of medications and allergies.

"We very much want well-intentioned providers to become meaningful users,'

Dr. David Blumenthal, National Coordinator for Health Information Technology at HHS, said during a press briefing to announce the final rule.

HHS officials also relaxed some of the thresholds related to the requirements. For example, under the proposed rule, physicians would have had to generate and transmit 75% of their permissible prescriptions electronically to meet the e-prescribing requirement. Under the final rule, the threshold has been lowered to more than 40% of permissible prescriptions, Dr. Blumenthal said.

The final rule also creates an easier path for physicians to meet meaningful use requirements on electronic reporting of quality data. Under the final rule, physicians will need to report data on blood pressure, tobacco status, and adult weight screening, and follow-up in 2011 and 2012, in order to qualify.

The final rule outlines steps physicians must take in 2011 and 2012 to quality for the maximum incentive payments through Medicare and Medicaid. The incentives were mandated by the Health Information Technology for Economic and Clinical Health Act (HITECH), a part of 2009's American Recovery Act.

Starting in 2011, physicians who show meaningful use of certified EHRs can receive payments of up to \$18,000 from Medicare. Those bonuses continue for 5 years, with physicians eligible to earn up to \$44,000 in total incentives.

### ONGLYZA™ (saxagliptin) tablets

Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.

#### INDICATIONS AND USAGE

### otherapy and Combi

ONGLYZA (saxagliptin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [See *Clinical Studies* (14).]

#### Important Limitations of Use

ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. ONGLYZA has not been studied in combination with insulin.

#### CONTRAINDICATIONS

#### WARNINGS AND PRECAUTIONS

#### Use with Medications Known to Cause Hypoglycemia

Insulin secretagogues, such as sulfonylureas, cause hypoglycemia. Therefore, a lower dose of the insulin secretagogue may be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA. [See Adverse Reactions (6.1).]

#### Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug.

#### ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

#### Monotherapy and Add-On Combination Therapy

In two placebo-controlled monotherapy trials of 24-weeks duration, patients were treated with ONGIYZA 2.5 mg daily, ONGIYZA 5 mg daily, and placebo. Three 24-week, placebo-controlled, add-on combination therapy trials were also conducted: one with metformin, one with a thiazolidinedione (pioglitazone associated with mental minimal problems of the grant problems of the problems of the grant problems of the monotherapy trials and in the add-on combination trial with metformin.

daily, or placebo. A saxaqliptin 10 mg treatment arm was included in one of the monotherapy trials and in the add-on combination trial with metformin.

In a prespecified pooled analysis of the 24-week data (regardless of glycemic rescue) from the two monotherapy trials, the add-on to metformin trial, the add-on to thizazoldinedione (TZD) trial, and the add-on to glyburide trial, the overall incidence of adverse events in patients treated with ONGLYZA 2.5 mg and ONGLYZA 5 mg was similar to placebo (72.0% and 72.2% versus 70.6%, espectively). Discontinuation of therapy due to adverse events occurred in 2.2%, 3.3%, and 1.8% of patients receiving ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. The most common adverse events occurred in 2.2%, 3.3%, and 1.8% of patients receiving ONGLYZA 2.5 mg or at least 2 patients treated with ONGLYZA 5.5 mg or at least 2 patients treated with ONGLYZA 5.5 mg or at least 2 patients treated with ONGLYZA 5 mg, and 0.3% versus 0.3%), blood creatinine increased (0.3% and 0.6% versus 0%), and blood creatine phosphokinase increased (0.1% and 0.2% versus 0%). The adverse reactions in this pooled analysis reported (regardless of investigator assessment of causality) in ≥5% of patients treated with ONGLYZA 5 mg, and more commonly than in patients treated with Placebo are shown in Table 1.

Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials\* Reported in ≥5% of Patients Treated with Placebo

Number (%) of Patients

	Number (%) of Patients	
	ONGLYZA 5 mg N=882	Placebo N=799
Upper respiratory tract infection	68 (7.7)	61 (7.6)
Urinary tract infection	60 (6.8)	49 (6.1)
Headache	57 (6.5)	47 (5.9)

The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.

In patients treated with ONGLYZA 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate ≥5% and more commonly than in patients treated with placebo.

In this pooled analysis, adverse reactions that were reported in ≥2% of patient treated with ONGLYZA 2.5 mg or ONGLYZA 5 mg and ≥1% more frequent compared to placebo included: sinusitis (2.9% and 2.6% versus 1.6% respectively), abdominal pain (2.4% and 1.7% versus 0.5%), gastroenteritis (1.9% and 2.3% versus 0.9%), and vomiting (2.2% and 2.3% versus 1.3%).

In the add-on to TZD trial, the incidence of peripheral edema was higher for ONGLYZA 5 mg versus placebo (8.1% and 4.3%, respectively). The incidence of peripheral edema for ONGLYZA 2.5 mg was 3.1%. None of the reported adverse reactions of peripheral edema resulted in study drug discontinuation Rates of peripheral edema for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.

2.2% given as add-on therapy to glyburide.

The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for ONGLYZA (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The incidence rate of fracture events in patients who received ONGLYZA did not increase over time. Causality has not been established and nonclinical studies have not demonstrated adverse effects of saxagliptin on bone.

An event of thrombocytopenia, consistent with a diagnosis of idiopathic thrombocytopenic purpura, was observed in the clinical program. The relationship of this event to ONGLYZA is not known. Adverse Reactions Associated with ONGLYZA (saxagliptin) Coadministered with Metformin in Treatment-Naive Patients with Type 2 Diabetes

Table 2 shows the adverse reactions reported (regardless of investigato assessment of causality) in ≥5% of patients participating in an additional assessment of causality) in ≥5% of patients participating in an additional 24-week, active-controlled trial of coadministered ONGLYZA and metformin in treatment-naive patients.

Initial Therapy with Combination of ONGLYZA and Metformin in Treatment-Naive Patients: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Treated with Combination Therapy of ONGLYZA 5 mg Plus Metformin (and More Com

	Number (%) of Patients		
	ONGLYZA 5 mg + Metformin* N=320	Metformin* N=328	
-leadache	24 (7.5)	17 (5.2)	
Nasopharyngitis	22 (6.9)	13 (4.0)	

Metformin was initiated at a starting dose of 500 mg daily and titrated up to a maximum of 2000 mg daily.

Adverse reactions of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required. In the add-on to glyburide study, the overall incidence of reported hypoglycemia was higher for ONGLYZA 2.5 mg and ONGLYZA 5 mg (13.3% and 14.6%) versus placebo (10.1%). The incidence of confirmed hypoglycemia in this study, defined as symptoms of hypoglycemia accompanied by a fingerstick glucose value of ≤50 mg/dL, was 2.4% and 0.8% for ONGLYZA 2.5 mg and ONGLYZA 5 mg and 0.7% for placebo. The incidence of reported hypoglycemia for ONGLYZA 5.5 mg and ONGLYZA 5 mg ersus placebo given as montherapy was 4.0% and 5.6% versus 4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to metformin, and 4.1% and 2.7% versus 3.4% in treatment-naive patients given ONGLYZA 5 mg plus metformin and 4.0% in patients given metformin alone.

\*\*Worsenstitivity Reactions\*\* Adverse reactions of hypoglycemia were based on all reports of hypoglycemia

### Hypersensitivity Reactions

Hypersensitivity-related events, such as urticaria and facial edema in the 5-study pooled analysis up to Week 24 were reported in 1.5%, 1.5%, and 0.4% of patients who received ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively. None of these events in patients who received ONGLYZA required hospitalization or were reported as life-threatening by the investigators. One saxagliptin-treated patient in this pooled analysis discontinued due to generalized urticaria and facial edema.

### Vital Signs

No clinically meaningful changes in vital signs have been observed in patients treated with ONGLYZA.

### **Laboratory Tests**

Absolute Lymphocyte Counts
There was a dose-related mean decrease in absolute lymphocyte count observed with ONGLYZA. From a baseline mean absolute lymphocyte count of approximately 2200 cells/microL, mean decreases of approximately 100 and 120 cells/microL with ONGLYZA 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled clinical studies. Similar effects were observed whon ONGLYZA 5 mg was given in initial combination with metrormin compared to metformin alone. There was no difference observed for ONGLYZA 2.5 mg relative to placebo. The proportion of patients who were reported to have a hymphocyte count Z50 cells/microL was 0.5%, 1.5%, 1.4%, and 0.4% in the saxagliptin 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively. In most patients, recurrence was not observed with repeated exposure to ONGLYZA although some patients had recurrent decreases upon rechallenge that led to although some patients had recurrent decreases upon rechallenge that led to discontinuation of ONGLYZA. The decreases in lymphocyte count were not associated with clinically relevant adverse reactions.

The clinical significance of this decrease in lymphocyte count relative to placebo is not known. When clinically indicated, such as in settings of unusual or prolonged infection, lymphocyte count should be measured. The effect of ONGLYZA on lymphocyte counts in patients with lymphocyte abnormalities (e.g., human immunodeficiency virus) is unknown.

ONGLYZA did not demonstrate a clinically meaningful or consistent effect on platelet count in the six, double-blind, controlled clinical safety and efficacy

### DRUG INTERACTIONS

Rifampin significantly decreased saxagliptin exposure with no change in the area under the time-concentration curve (AUC) of its active metabolite, 5-hydroxy saxagliptin. The plasma dipeptidyl peptidase-4 (DPP4) activity inhibition over a 24-hour dose interval was not affected by rifampin. Therefore, dosage adjustment of ONGLYZA is not recommended. [See Clinical Pharmacology (12.3).]

Moderate Inhibitors of CYP3A4/5

moute ate infinitions of CFF344/3
Dilitiazem increased the exposure of saxagliptin. Similar increases in plasma concentrations of saxagliptin are anticipated in the presence of other moderate CYP344/5 inhibitors (e.g., amprenavir, aprepitant, erythromycin, fluconazole fosamprenavir, grapefruit juice, and verapamil); however, dosage adjustment of ONGLYZA is not recommended. [See Clinical Pharmacology (12.3).]

### Strong Inhibitors of CYP3A4/5

Ketoconazole significantly increased saxagliptin exposure. Similar sigincreases in plasma concentrations of saxagliptin are anticipated with othe strong CYP3A4/5 inhibitors (e.g., atazanavir, clarithromycin, indinavir itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) The dose of ONGLYZA should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor. [See *Dosage and Administration (2.3)* and *Clinica* 

#### USE IN SPECIFIC POPULATIONS

### Pregnancy Category B

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, OMGIYA (saxagliphin), like other antidiabetic medications, should be used during pregnancy only if clearly needed.

response, ONGLYZA (saxagliptin), like other artidiabetic medications, should be used during pregnancy only if clearly needed.

Saxagliptin was not teratogenic at any dose tested when administered to pregnant rats and rabbits during periods of organogenesis. Incomplete ossification of the pelvis, a form of developmental delay, occurred in rats at a dose of 240 mg/kg, or approximately 1503 and 66 times human exposure to saxagliptin and the active metabolite, respectively, at the maximum recommended human dose (MRHD) of 5 mg. Maternal toxicity and reduced fetal body weights were observed at 7986 and 328 times the human exposure at the MRHD for saxagliptin and the active metabolite, respectively, Minor skeletal variations in rabbits occurred at a maternally toxic dose of 200 mg/kg, or approximately 1432 and 992 times the MRHD. When administered to rats in combination with metformin, saxagliptin was not teratogenic nor embryolethal at exposures 21 times the saxagliptin MRHD. Combination administration of metformin with a higher dose of saxagliptin (109 times the saxagliptin MRHD) was associated with craniorachischisis (a rare neural tube defect characterized by incomplete closure of the skull and spinal column) in two fetuses from a single dam. Metformin exposures are each combination were 4 times the human exposure of 2000 mg daily.

Saxagliptin administered to female rats from gestation day 6 to lactation day 20 resulted in decreased body weights in male and female offspring only at maternally toxic doses (exposures ≥1629 and 53 times saxagliptin and its active metabolite at the MRHD). No functional or behavioral toxicity was observed in offspring of rats administered saxagliptin at program frats.

#### Saxagliptin crosses the placenta into the fetus following dosing in pregnant rats **Nursing Mothers**

Saxagliptin is secreted in the milk of lactating rats at approximately a 1:1 ratio with plasma drug concentrations. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when ONGLYZA is administered to a nursing

#### Pediatric Use

Safety and effectiveness of ONGLYZA in pediatric patients have not beer established.

In the six, double-blind, controlled clinical safety and efficacy trials of ONGLYZA In the six, double-blind, controlled clinical safety and efficacy trails of ONGLY/A, 634 (15.3%) of the 4148 randomized patients were 65 years and over, and 59 (1.4%) patients were 75 years and over. No overall differences in safety or effectiveness were observed between patients ≥65 years old and the younger patients. While this clinical experience has not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.

Saxagliptin and its active metabolite are eliminated in part by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function. [See Dosage and Administration (2.2) and Clinical Pharmacology (12.3).]

In a controlled clinical trial, once-daily, orally-administered ONGLYZA in healthy subjects at doses up to 400 mg daily for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on OTc interval or heart rate.

### PATIENT COUNSELING INFORMATION

### See FDA-approved patient labeling.

Patients should be informed of the potential risks and benefits of ONGLYZA and of alternative modes of therapy. Patients should also be informed about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and A1C testing, recognition and management of hypoglycemia and hyperglycemia, and assessment of diabetes complications. During periods of stress such as fever, trauma, infection, or surgery, medication requirements may change and patients should be advised to seek medical advice promptly.

Physicians should instruct their patients to read the Patient Package Insert before starting ONGLYZA therapy and to reread it each time the prescription is renewed. Patients should be instructed to inform their doctor or pharmacist if they develop any unusual symptom or if any existing symptom persists

### Laboratory Tests

Patients should be informed that response to all diabetic therapies be monitored by periodic measurements of blood glucose and ATC, goal of decreasing these levels toward the normal range. A1C is es useful for evaluating long-term glycemic control. Patients should be informed of the potential need to adjust their dose based on changes in renal function ests over time.



Marketed by:

Bristol-Myers Squibb Company Princeton, NJ 08543

AstraZeneca Pharmaceuticals LP Wilmington, DE 19850

> SA-B0001A-07-09 Iss July 2009

## INDEX OF **ADVERTISERS**

Alcon, Inc. Pataday	55-56
Astellas Pharma US, Inc. Http://www.infectiousdiseasesno	etwork.com/fungalrisk 29
Bayer HealthCare LLC Aleve	31
Bristol-Myers Squibb Onglyza	78-80
Forest Pharmaceuticals, Inc.	70 00
Namenda	4a-4b
Lexapro	15-19
Savella	37-40
Bystolic	47-50
GlaxoSmithKline Consumer Hea	Ithcare
Tums	53
Kowa Pharmaceuticals America	
Livalo	76a-76b
Lilly USA, LLC	
Humalog	32-34
Novo Nordisk A/S	
Victoza	42-44
Novo Nordisk Inc.	
NovoLog	25-26
Levemir	51-52
Pfizer Inc.	
Lipitor	3-4
Corporate	7
Lyrica	21-23
Zmax	27-28
Pristiq	73-74
Rexall Sundown, Inc. Osteo Bi-Flex	13
sanofi-aventis U.S. LLC	0.12
Lantus SoloStar Corporate	8-12 60-61, 68-69
Corporate	00-01, 00-09

Takeda Pharmaceuticals North America, Inc.